Press Release

Illumina to Announce Second Quarter 2015 Financial Results on Tuesday, July 21, 2015

SAN DIEGO--(BUSINESS WIRE)--Jul. 7, 2015-- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for second quarter 2015 following the close of market on Tuesday, July 21, 2015.

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jay Flatley, Chief Executive Officer, Francis deSouza, President, and Marc Stapley, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Tuesday, July 21, 2015. Interested parties may listen to the call by dialing 877.703.6110 (passcode: 79927332), or if outside North America by dialing +1.857.244.7309 (passcode: 79927332). Individuals may access the live teleconference in the Investor Relations section of Illumina’s web site under the “Company” tab at www.illumina.com.

A replay of the conference call will be available from 6:00 pm Pacific Time (9:00 pm Eastern Time) on July 21, 2015 through July 28, 2015 by dialing 888.286.8010 (passcode: 76382666), or if outside North America by dialing +1.617.801.6888 (passcode: 76382666).

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Eric Endicott, 858-882-6822
pr@illumina.com

Recent Articles

Engineering a cool career in biotech—and volunteering along the way
Engineering a cool career in biotech—and volunteering along the way
Evidence supports sequencing as first-line rare disease diagnostic
Evidence supports sequencing as first-line rare disease diagnostic
Podcast stories explore unusual and surprising applications of genomics
Podcast stories explore unusual and surprising applications of genomics